Libby Uhlenhopp
Family · Parkersburg, IANPI 1548720998
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,576 of the $13,041 with a category attached, or 73.4%. 21 manufacturers reported payments, led by Viatris Specialty LLC at 52.6% of the total. 2025 is the largest year on record at $7,261, more than ten times the $237 reported in 2021. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $108.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viatris Specialty LLC$7K
- Mylan Specialty L.p.$5K
- AbbVie$255
- GSK$243
- AstraZeneca$201
- Novo Nordisk$146
- plus $648 from 15 others
What the payments were for
- Speaking & faculty fees$9,57673%
- Travel & lodging$1,49411%
- Food & beverage$1,93915%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viatris Specialty LLC | 14 | $6,855 |
| Mylan Specialty L.p. | 25 | $4,693 |
| AbbVie | 15 | $255 |
| GSK | 23 | $243 |
| AstraZeneca(2 entities) | 6 | $201 |
| Novo Nordisk | 5 | $146 |
| Phathom Pharmaceuticals, Inc. | 4 | $136 |
| Amgen | 8 | $121 |
| Lilly USA, LLC | 5 | $85 |
| Johnson & Johnson | 2 | $80 |
| Alkermes, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Indivior Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Pfizer | 1 | $18 |
| Corium, LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$11,016
How this compares
$13,041 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 29 | $30,091 |
| OzempicSemaglutide | 20 | $17,331 |
| JardianceEmpagliflozin | 15 | $12,504 |
| MyrbetriqMirabegron | 20 | $11,958 |
| EliquisApixaban | 13 | $10,967 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $8,804 |
| DapagliflozinDapagliflozin Propanediol | 15 | $7,256 |
| BelsomraSuvorexant | 11 | $4,827 |
| JanuviaSitagliptin Phosphate | 12 | $4,456 |
| Ranolazine ErRanolazine | 15 | $1,182 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 55 | $977 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $630 |
| Atorvastatin Calcium | 56 | $601 |
| Gabapentin | 34 | $543 |
| Bupropion XlBupropion Hcl | 18 | $531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $85 | $30,09129 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $36 | $21,30834 claims |
| Novo NordiskOzempic | $146 | $17,33120 claims |
| PfizerEliquis | $18 | $10,96713 claims |
| MerckBelsomra, Januvia | $14 | $9,28423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Parkersburg
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.